Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. Show more

Location: 2656 State Street, Carlsbad, CA, 92008, United States | Website: https://tyra.bio | Industry: Biotechnology | Sector: Healthcare


Market Cap

656.1M

52 Wk Range

$6.42 - $29.60

Previous Close

$12.31

Open

$12.27

Volume

173,104

Day Range

$12.10 - $12.53

Enterprise Value

365.8M

Cash

296.3M

Avg Qtr Burn

-21.66M

Insider Ownership

3.68%

Institutional Own.

-

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.